Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for Thrombosis Prevention in Primary APS
NCT04153201Completed
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Jan 2013
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxychloroquine in antiphospholipid syndrome (APS) (2 arms), sponsored by National and Kapodistrian University of Athens. Primary endpoint: Incident acute thrombosis in the venous or arterial circulation at 3 years. Started Jan 2013; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT04153201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153201.